Travere Therapeutics, FILSPARI, Sparsentan, IgA Nephropathy, IgAN, Kidney Disease, Nephrology, PROTECT Study, Phase 3 Clinical Trial, ASN Kidney Week 2026, Biomarkers,

SAN DIEGO, Calif. — October 23, 2026 Travere Therapeutics, Inc. presented new biomarker findings from its Phase 3 PROTECT...